Mobile

A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by diet and e...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-001049-25

A clinical trial to test if the combination of ertugliflozin with Sitagliptin is safe when compared to placebo in patients with Type 2 Diabetes whose sugar levels are not well controlled by diet and excercise

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

In subjects with T2DM and inadequate glycemic control on diet and exercise, after 26 weeks: 1. To assess the A1C-lowering efficacy of ertugliflozin 15 mg q.d. plus sitagliptin 100 mg q.d. relative to placebo. 2. To assess the A1C-lowering efficacy of ertugliflozin 5 mg q.d. plus sitagliptin 100 mg q.d. relative to placebo. 3. To assess the safety and tolerability of ertugliflozin plus sitagliptin 100 mg q.d.

Critère d'inclusion

  • Treatment of type 2 diabetes mellitus (T2DM) with Inadequate Glycemic Control on Diet and Exercise

Liens